• Products

    A Guide to Hartford Funds

    View Now >

  • Insights

    The Reimagined Human-Centric Investing Podcast

    See What's New >

  • Practice Management

    Applied Insights Team

    Learn More >

  • Resources

    Tax Center

    View Now >

  • About Us

    Be Human-Centric

    Learn More >

Domestic Equity fund

Hartford Healthcare HLS Fund    Share Class - HLS IA (HIAHX)


MORNINGSTAR RATING:
Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 140, 140, 130 and 106 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
overall (as of 10/31/2021)
140 PRODUCTS
Health Category
Based on Risk-Adjusted Returns

Key Documents
      Actions

      Effective 12/31/17, this Fund is closed to certain qualified pension and retirement plans.  For more information, please refer to the fund's statutory prospectus.

      Objective

      Seeks long-term capital appreciation.

      Overview

      A stock fund that invests in health care, a sector that is experiencing innovations and breakthroughs across multiple subsectors.

      Portfolio Management
      Senior Managing Director
      Global Industry Analyst
      21
      YRS
      MANAGING THIS FUND
      23
      YRS
      AT WELLINGTON MANAGEMENT
      34
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Senior Managing Director
      Global Industry Analyst
      17
      YRS
      MANAGING THIS FUND
      21
      YRS
      AT WELLINGTON MANAGEMENT
      38
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Senior Managing Director
      Global Industry Analyst
      1
      YRS
      MANAGING THIS FUND
      14
      YRS
      AT WELLINGTON MANAGEMENT
      16
      YRS
      EXPERIENCE IN THIS INDUSTRY
      Managing Director
      Global Industry Analyst
      0
      YRS
      MANAGING THIS FUND
      6
      YRS
      AT WELLINGTON MANAGEMENT
      14
      YRS
      EXPERIENCE IN THIS INDUSTRY

      The portfolio managers are supported by the full resources of Wellington.

      Performance

      PERFORMANCE %
       
      CUMULATIVE %
      (as of 10/31/2021)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 10/31/2021)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare HLS IA 8.85 23.01 19.34 17.23 17.94 12.92
      Benchmark 18.62 33.53 16.90 17.21 17.26 ---
      Morningstar Health Category 8.34 25.98 16.75 16.70 16.54 ---
       
      CUMULATIVE %
      (as of 9/30/2021)
      AVERAGE ANNUAL TOTAL RETURNS %
      (as of 9/30/2021)
      YTD 1YR 3YR 5YR 10YR SI
      Hartford Healthcare HLS IA 5.91 17.08 13.80 14.62 18.37 12.83
      Benchmark 13.10 23.18 12.28 14.51 17.38 ---
      Morningstar Health Category 5.69 20.86 11.46 13.75 16.95 ---

      Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

      SI = Since Inception. Fund Inception: 05/01/2000

      Prior to 4/1/2016, the Fund's benchmark was the S&P North American Health Care Sector Index.

      Hartford Healthcare HLS Fund IA Share Morningstar Ratings
      overall
      (as of 10/31/2021)
      Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 140, 140, 130 and 106 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

      140 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      3 YEAR
      (as of 10/31/2021)
      Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 140, 140, 130 and 106 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

      140 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      5 YEAR
      (as of 10/31/2021)
      Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 140, 140, 130 and 106 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

      130 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns
      10 YEAR
      (as of 10/31/2021)
      Overall, 4 stars, 3-Year, 4 stars, 5-Year, 3 stars, and 10-Year, 4 stars, rated against 140, 140, 130 and 106 products, respectively. Morningstar RatingTM is calculated for products with at least a 3-year history, based on a risk-adjusted return measure (excluding any applicable sale charges) and accounts for variations in a product's monthly performance. 5 stars are assigned to the top 10%; 4 stars to the next 22.5%, 3 stars to the next 35%, 2 stars to the next 22.5% and 1 star to the bottom 10%. ETFs and mutual funds are considered a single population. The Overall Rating is derived from a weighted average of the performance figures associated with its 3-, 5-, and 10-year (if applicable) Morningstar Rating metrics. For more information about these ratings, including their methodology, please go to global.morningstar.com/managerdisclosures . Ratings for other share classes may vary and are subject to change monthly. Past performance is no guarantee of future performance.
      ©2021 Morningstar, Inc. All rights reserved. The information contained herein: (1) is proprietary to Morningstar and/ or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

      106 PRODUCTS
      |
      Health Category
      Based on Risk-Adjusted Returns

      Characteristics

      FUND ESSENTIALS
      Inception Date 05/01/2000
      Net Assets $209 million
      Total Operating Expenses 0.91%
      Morningstar Category Health
      Lipper Classification Global Health/Biotechnology Funds
      CUSIP 416528719
      Fund Number 2055
      FUND STATS
      # of Holdings
      107
      % in Equities
      98
      % in Foreign Equities
      18
      Beta (3 year)
      1.01
      R Squared (3 year)
      0.87
      Standard Deviation
      17.00%
      Turnover- (9/30/2021)
      50%
      Active Share
      61%
      Holdings Characteristics
      FUND S&P Composite 1500 Health Care Index
      Price/Earnings
      32.0x 16.8x
      Price/Book
      5.7x 5.7x
      EPS Growth Rate
      12.4% 10.3%
      Asset Weighted Market Cap (billions)
      $111.9 $172.9
      Return on Equity
      9.1% 21.4%
      Median Market Cap (billions)
      $7.6 $5.5
      Top Holdings (%)
      UnitedHealth Group, Inc. 9.19
      Pfizer, Inc. 5.70
      Eli Lilly & Co. 5.23
      Danaher Corp. 3.90
      Bristol-Myers Squibb Co. 3.37
      Boston Scientific Corp. 3.04
      Edwards Lifesciences Corp. 3.02
      Stryker Corp. 2.62
      AstraZeneca plc 2.37
      Zoetis, Inc. 2.37
      Total Portfolio % 40.81
      UnitedHealth Group, Inc. 8.01
      Pfizer, Inc. 5.44
      Eli Lilly & Co. 5.08
      Danaher Corp. 3.91
      Boston Scientific Corp. 3.14
      Bristol-Myers Squibb Co. 2.95
      Edwards Lifesciences Corp. 2.93
      Stryker Corp. 2.67
      AstraZeneca plc 2.35
      Zoetis, Inc. 2.18
      Total Portfolio % 38.66
      Market Cap Distribution (%)

      Market Cap Header3

      Less than $2 billion 5
      $2 billion - $5 billion 9
      $5 billion - $10 billion 11
      Greater than $10 billion 74
      Not Classified 0
      Subsector Exposure
      Medical Technology 33
      Biopharma Large Cap 27
      Health Care Services 23
      Biopharma Mid Cap 13
      Biopharma Small Cap 4
      Medical Technology 34
      Biopharma Large Cap 26
      Health Care Services 21
      Biopharma Mid Cap 13
      Biopharma Small Cap 5
      Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
      distributions and capital gains
      Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
      8/27/2021 23.87 $0.0559 $0.7973 $1.8823 $2.7355
      Past distributions are not indicative of future distributions.

      Fund Literature


      09/30/2021 - PDF (357 KB)
      Current quarterly commentary from our sub-adviser, Wellington Management, which includes a performance review, attribution, statistics, and positioning and outlook for the Fund.
      PDF (145 KB)
      A summary of a fund's full-length prospectus that provides key information potential investors should consider before making an investment decision.
      PDF (2 KB)
      An unaudited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      PDF (13 KB)
      A legal document that discloses essential information about a fund, including investment objectives, risks, fees, expenses, fund manager background and other information.
      PDF (2 KB)
      An audited financial report, which includes a fund's financial statements. These reports are intended for shareholders and others who have reviewed the fund's prospectus.
      PDF (13 KB)
      A document that supplements the fund's prospectus with additional information about the fund including its operations and risks.
      Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, patent considerations, intense competitive pressures, rapid technological changes, potential product obsolescence, and liquidity risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments. These risks may be greater, and include additional risks, for investments in emerging markets.

      Hartford HLS Funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). The funds are sub-advised by Wellington Management Company LLP, which is not affiliated with HFD and HFMC.

       

      224991

      The material on this site is for informational and educational purposes only. The material should not be considered tax or legal advice and is not to be relied on as a forecast. The material is also not a recommendation or advice regarding any particular security, strategy or product. Hartford Funds does not represent that any products or strategies discussed are appropriate for any particular investor so investors should seek their own professional advice before investing. Hartford Funds does not serve as a fiduciary. Content is current as of the publication date or date indicated, and may be superseded by subsequent market and economic conditions.

      Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the mutual fund, or ETF summary prospectus and/or prospectus, which can be obtained from a financial professional and should be read carefully before investing.

      Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA/SIPC. ETFs are distributed by ALPS Distributors, Inc. (ALPS). Advisory services may be provided by Hartford Funds Management Company, LLC (HFMC) or its wholly owned subsidiary, Lattice Strategies LLC (Lattice). Certain funds are sub-advised by Wellington Management Company LLP and/or Schroder Investment Management North America Inc. Schroder Investment Management North America Ltd. serves as a secondary sub-adviser to certain funds. Hartford Funds refers to Hartford Funds Management Group, Inc. and its subsidiaries, including HFD, HFMC, and Lattice, which are not affiliated with any sub-adviser or ALPS. The funds and other products referred to on this Site may be offered and sold only to persons in the United States and its territories.

      © Copyright 2021 Hartford Funds Management Group, Inc. All Rights Reserved. Not FDIC Insured | No Bank Guarantee | May Lose Value